Company Overview - Shangrong Medical's closing price on August 22 was 4.63 yuan, down 1.07%, with a rolling PE ratio of 175.05 times and a total market value of 3.915 billion yuan [1] - The company operates in the medical device industry, which has an average PE ratio of 56.95 times and a median of 40.49 times, placing Shangrong Medical at the 112th position in industry rankings [1][2] - As of March 31, 2025, the number of shareholders was 58,323, a decrease of 621 from the previous count, with an average holding value of 352,800 yuan and an average holding of 27,600 shares per shareholder [1] Business Operations - Shangrong Medical specializes in the production and sales of medical products, medical services, and health industry operations [1] - The company is recognized as one of the earliest to introduce clean technology into hospital operating rooms in China [1] - Its intelligent self-controlled operating room products have received multiple national honors, including recognition from the Ministry of Science and Technology and the Shenzhen Municipal Government [1] Patent and Innovation - The company and its subsidiaries have obtained over 180 patents, which serve as a driving force for its continuous development [1] Financial Performance - In the first quarter of 2025, Shangrong Medical reported an operating income of 280 million yuan, a year-on-year increase of 1.30%, and a net profit of 13.9642 million yuan, reflecting a year-on-year growth of 0.58% [2] - The sales gross margin for the same period was 15.27% [2]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Shangrong Medical, indicating a significant disparity between its high PE ratio and the industry average [1][2] - As of August 20, Shangrong Medical's stock closed at 4.95 yuan, down 4.81%, with a rolling PE ratio of 187.15 times, compared to the industry average of 59.32 times [1] - The company has a total market capitalization of 4.185 billion yuan, ranking 111th in the medical device industry based on PE ratio [1][2] Group 2 - For Q1 2025, Shangrong Medical reported revenue of 280 million yuan, a year-on-year increase of 130%, and a net profit of 13.9642 million yuan, reflecting a year-on-year growth of 0.58% [2] - The company's gross profit margin stands at 15.27% [2] - The company has been recognized as a national high-tech enterprise and has accumulated over 180 patents, which are crucial for its ongoing development [1]

深圳市尚荣医疗股份有限公司的主营业务是医疗产品生产销售、医疗服务、健康产业运营等。公司的主 要产品是医疗服务、医疗产品生产销售、健康产业运营。公司是国内最早将洁净技术引入医院手术部的 企业之一，公司的智能自控手术室产品荣获国家科技部、商务部、质量监督总局及环保总局颁发的国家 重点新产品荣誉，荣获深圳市人民政府颁发的科学技术进步二等奖，荣获深圳市科技和信息局颁发的高 新技术项目。公司是国家级高新技术企业、深圳市自主创新行业领军企业之一、深圳市高新技术企业、 深圳市知识产权优势企业。公司及子公司累计获得超过180项专利，成为公司持续发展的源动力。 8月18日，尚荣医疗今日收盘5.09元，上涨4.52%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到192.44倍，创642天以来新低，总市值43.04亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均58.46倍，行业中值40.51倍，尚荣医疗排 名第113位。 股东方面，截至2025年3月31日，尚荣医疗股东户数58323户，较上次减少621户，户均持股市值35.28万 元，户均持股数量2.76万股。 序号股票简称PE(TTM)PE(静) ...

从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均55.76倍，行业中值39.14倍，尚荣医疗排 名第112位。 8月14日，尚荣医疗今日收盘4.43元，下跌7.71%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到167.49倍，总市值37.46亿元。 股东方面，截至2025年3月31日，尚荣医疗股东户数58323户，较上次减少621户，户均持股市值35.28万 元，户均持股数量2.76万股。 来源：金融界 深圳市尚荣医疗股份有限公司的主营业务是医疗产品生产销售、医疗服务、健康产业运营等。公司的主 要产品是医疗服务、医疗产品生产销售、健康产业运营。公司是国内最早将洁净技术引入医院手术部的 企业之一，公司的智能自控手术室产品荣获国家科技部、商务部、质量监督总局及环保总局颁发的国家 重点新产品荣誉，荣获深圳市人民政府颁发的科学技术进步二等奖，荣获深圳市科技和信息局颁发的高 新技术项目。公司是国家级高新技术企业、深圳市自主创新行业领军企业之一、深圳市高新技术企业、 深圳市知识产权优势企业。公司及子公司累计获得超过180项专利，成为公司持续发展的源动力。 最新一期业绩显示，2025年一季报，公司实 ...

深圳市尚荣医疗股份有限公司的主营业务是医疗产品生产销售、医疗服务、健康产业运营等。公司的主 要产品是医疗服务、医疗产品生产销售、健康产业运营。公司是国内最早将洁净技术引入医院手术部的 企业之一，公司的智能自控手术室产品荣获国家科技部、商务部、质量监督总局及环保总局颁发的国家 重点新产品荣誉，荣获深圳市人民政府颁发的科学技术进步二等奖，荣获深圳市科技和信息局颁发的高 新技术项目。公司是国家级高新技术企业、深圳市自主创新行业领军企业之一、深圳市高新技术企业、 深圳市知识产权优势企业。公司及子公司累计获得超过180项专利，成为公司持续发展的源动力。 最新一期业绩显示，2025年一季报，公司实现营业收入2.80亿元，同比1.30%；净利润1396.42万元，同 比0.58%，销售毛利率15.27%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13尚荣医疗180.72181.381.5340.41亿行业平均 57.5153.344.97120.28亿行业中值41.2539.962.9558.75亿1九安医疗11.2611.380.89189.95亿2英科医疗 15.0516.231.34237.81亿3山东 ...

Core Viewpoint - 尚荣医疗's stock closed at 3.84 yuan, down 2.29%, with a rolling PE ratio of 145.18 times, and a total market value of 3.247 billion yuan [1] Company Overview - Shenzhen 尚荣医疗股份有限公司 specializes in the production and sales of medical products, medical services, and health industry operations [1] - The company is one of the earliest to introduce clean technology into hospital operating rooms in China [1] - 尚荣医疗 has received numerous honors, including national key new product recognition and awards from the Shenzhen municipal government for technological progress [1] - The company holds over 180 patents, which are a key driver of its continuous development [1] Financial Performance - In Q1 2025, the company reported operating revenue of 280 million yuan, a year-on-year increase of 30% [2] - Net profit for the same period was 13.9642 million yuan, reflecting a year-on-year growth of 0.58% [2] - The sales gross margin stood at 15.27% [2] Industry Comparison - The average PE ratio for the medical device industry is 53.93 times, with a median of 37.81 times, placing 尚荣医疗 at 111th in the industry ranking [1][2] - The company's PE (TTM) is significantly higher than the industry average, indicating potential overvaluation [2]

8月4日，尚荣医疗今日收盘3.95元，上涨1.28%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到149.34倍，创17天以来新低，总市值33.40亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均54.31倍，行业中值38.11倍，尚荣医疗排 名第110位。 股东方面，截至2025年3月31日，尚荣医疗股东户数58323户，较上次减少621户，户均持股市值35.28万 元，户均持股数量2.76万股。 深圳市尚荣医疗股份有限公司的主营业务是医疗产品生产销售、医疗服务、健康产业运营等。公司的主 要产品是医疗服务、医疗产品生产销售、健康产业运营。公司是国内最早将洁净技术引入医院手术部的 企业之一，公司的智能自控手术室产品荣获国家科技部、商务部、质量监督总局及环保总局颁发的国家 重点新产品荣誉，荣获深圳市人民政府颁发的科学技术进步二等奖，荣获深圳市科技和信息局颁发的高 新技术项目。公司是国家级高新技术企业、深圳市自主创新行业领军企业之一、深圳市高新技术企业、 深圳市知识产权优势企业。公司及子公司累计获得超过180项专利，成为公司持续发展的源动力。 最新一期业绩显示，2025年一季报，公司 ...

序号股票简称PE(TTM)PE(静)市净率总市值(元)13尚荣医疗147.45147.991.2532.97亿行业平均 53.6550.024.68114.74亿行业中值37.2237.112.6755.30亿1九安医疗11.0111.130.87185.78亿2英科医疗 15.4516.651.37244.06亿3新华医疗15.7214.571.28100.77亿4山东药玻16.0216.071.84151.57亿5振德医疗 16.2915.351.0459.13亿6奥美医疗16.4116.081.6959.27亿7九强生物17.4416.212.1486.36亿8康德莱 17.6117.631.4637.96亿9维力医疗17.6918.902.2341.47亿10奥泰生物18.1519.141.4757.89亿11鱼跃医疗 19.8419.462.68351.37亿12安图生物20.0619.152.58228.74亿 股东方面，截至2025年3月31日，尚荣医疗股东户数58323户，较上次减少621户，户均持股市值35.28万 元，户均持股数量2.76万股。 来源：金融界 8月1日，尚荣医疗今日收盘3. ...

深圳市尚荣医疗股份有限公司的主营业务是医疗产品生产销售、医疗服务、健康产业运营等。公司的主 要产品是医疗服务、医疗产品生产销售、健康产业运营。公司是国内最早将洁净技术引入医院手术部的 企业之一，公司的智能自控手术室产品荣获国家科技部、商务部、质量监督总局及环保总局颁发的国家 重点新产品荣誉，荣获深圳市人民政府颁发的科学技术进步二等奖，荣获深圳市科技和信息局颁发的高 新技术项目。公司是国家级高新技术企业、深圳市自主创新行业领军企业之一、深圳市高新技术企业、 深圳市知识产权优势企业。公司及子公司累计获得超过180项专利，成为公司持续发展的源动力。 最新一期业绩显示，2025年一季报，公司实现营业收入2.80亿元，同比1.30%；净利润1396.42万元，同 比0.58%，销售毛利率15.27%。 来源：金融界 7月29日，尚荣医疗今日收盘3.8元，下跌1.30%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到143.67倍，总市值32.13亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均55.46倍，行业中值37.74倍，尚荣医疗排 名第109位。 股东方面，截至2025年3月31日， ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Shangrong Medical, indicating a high PE ratio compared to industry averages [1][2] - As of July 22, Shangrong Medical's stock closed at 3.82 yuan, with a PE ratio of 144.43, significantly higher than the industry average of 53.47 [1] - The company has experienced a net outflow of 279.90 thousand yuan in principal funds on July 22, with a total outflow of 1,735.96 thousand yuan over the past five days [1] Group 2 - In the latest quarterly report for Q1 2025, the company reported revenue of 280 million yuan, a year-on-year increase of 130%, and a net profit of 13.96 million yuan, a year-on-year increase of 0.58% [2] - The company's gross profit margin stands at 15.27% [2] - Shangrong Medical is recognized as a national high-tech enterprise and has received numerous awards and honors, including over 180 patents, which contribute to its ongoing development [1]